Vaccination is an efficient and cost-effective strategy to combat and eradicate deadly infectious diseases. Oral vaccines enable stimulation of protective mucosal and systemic immune responses to establish broader and long-lasting protection. Additionally, oral delivery has its other merits like enhanced patient compliance, price-effectiveness, large-scale production, no harm and infection from the needle and so one.
Lactic acid bacteria (LAB) are considered potential candidates as mucosal vaccine vectors. One major advantage of recombinant LAB strains as delivery vehicles for vaccines is their potential to elicit specific systemic and mucosal immune responses against selected antigens. One vaccine is Whole-Cell LAB-Based Vaccines that express the receptor binding domain (RBD) of the SARS-CoV-2. The spike (S) protein of coronaviruses mediates receptor binding and membrane fusion and is crucial for determining host tropism and transmission capacity.
Fig.1 Food grade vaccines based on lactic acid bacteria.
Creative Biogene provides a "one-stop shop" tailored to your SARS-CoV-2 oral vaccines research needs. We have expertise in genome editing (knock in) and gene expression. Creative Biogene is able to provide you the comprehensive service, including Lactobacillus spp. expression system, etc. Creative Biogene is dedicated to providing complete solutions to help you every step of the way in SARS-CoV-2 protein expression workflow. Simply let us know how you want the SARS-CoV-2 related gene to be expressed. We will propose the best strategy for you.
The following is the details of available Lactic acid bacteria protein expressing strains at Creative Biogene:
|SLE001||Lactobacillus spp.-SARS-CoV-2 S1(subunit 1) Protein Expression||Genome knock in|
|SLE002||Lactobacillus spp.-SARS-CoV-2 S2(subunit 2) Protein Expression||Genome knock in|
|SLE003||Lactobacillus spp.-SARS-CoV-2 RBD Expression||Genome knock in|
|SLE004||Lactobacillus spp.-SARS-CoV-2 S1(subunit 1) Protein Expression||Vector expression|
|SLE005||Lactobacillus spp.-SARS-CoV-2 S2(subunit 2) Protein Expression||Vector expression|
|SLE006||Lactobacillus spp.-SARS-CoV-2 RBD Expression||Vector expression|
1. Criscuolo, E. , Caputo, V. , Diotti, R. A. , Sautto, G. A. , Kirchenbaum, G. A. , & Clementi, N. . (2019). Alternative methods of vaccine delivery: an overview of edible and intradermal vaccines. Journal of Immunology Research, 2019, 1-13.
2. Lee, J. S. , Poo, H. , Han, D. P. , Hong, S. P. , Kim, K. , & Cho, M. W. , et al. (2006). Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on lactobacillus casei induces neutralizing antibodies in mice. Journal of Virology, 80(8), 4079-4087.
3. Szatraj, K., Szczepankowska, A. K., & Chmielewska-Jeznach, M. (2017). Lactic acid bacteria - promising vaccine vectors: possibilities, limitations, doubts. Journal of Applied Microbiology, 123(2), 325–339.